Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Azacitidine in Combination With Venetoclax Treatment for Prevention of Relapse in MRD Positive Post Allogeneic Hematopoietic Stem Cell Transplantation Acute Myelogenous Leukemia/ Myelodysplastic Syndrome Patients

NCT04809181 is registered in ClinicalTrials.gov with First Affiliated Hospital of Zhejiang University as lead sponsor.

NCT NCT04809181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04809181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Azacitidine in Combination With Venetoclax Treatment for Prevention of Relapse in MRD Positive Post Allogeneic Hematopoietic Stem Cell Transplantation Acute Myelogenous Leukemia/ Myelodysplastic Syndrome Patients
Lead sponsor
First Affiliated Hospital of Zhejiang University
Phase
Phase 2
Overall status
Unknown status
Start date
March 19, 2021
Completion date
March 19, 2026
Enrollment
95 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancy, stem cell transplant complications